Previous 10 | Next 10 |
TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company's lead product candidate, EB01, as a monotherapy for patie...
Gainers: Helios and Matheson Analytics ( OTCPK:HMNY ) +42% . McDermott International (NYSE: MDR ) +31% . Midatech Pharma plc (NASDAQ: MTP ) +30% . Stage Store (NYSE: SSI ) +26% . San Juan Basin Royalty Trust (NYSE: SJT ) +20% . Interlink Electronics ( OTCPK:LINK ) +20% . California ...
Gainers: SPI Energy Co. (NASDAQ: SPI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +22% . DAVIDsTEA (NASDAQ: DTEA ) +17% . Dynagas LNG Partners LP (NYSE: DLNG ) +12% . Edesa Biotech (NASDAQ: EDSA ) +12% . SCYNEXIS (NASDAQ: SCYX ) +11% . Eyenovia (NASDAQ: EYEN ) +10% . elect...
Gainers : Pier 1 Imports (NYSE: PIR ) +28% . Endo International (NASDAQ: ENDP ) +24% . Autolus Therapeutics (NASDAQ: AUTL ) +25% . Microbot Medical (NASDAQ: MBOT ) +24% . Hovnanian Enterprises (NYSE: HOV ) +20% . Lannett Company (NYSE: LCI ) +20% . DocuSign (NASDAQ: DOCU ) +19% . Su...
Gainers: Edesa Biotech (NASDAQ: EDSA ) +88% . G-III Apparel Group (NASDAQ: GIII ) +26% . Signet Jewelers (NYSE: SIG ) +22% . Pareteum Corporation (NASDAQ: TEUM ) +20% . Vista Oil & Gas S.A.B. de C.V. (NYSE: VIST ) +18% . Forward Industries (NASDAQ: FORD ) +17% . Lands' End ...
Signet Jewelers (NYSE: SIG ) +29% on Q2 results . More news on: Signet Jewelers Limited, Edesa Biotech, Inc., Global Blood Therapeutics, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Edesa Biotech (NASDAQ: EDSA ) is up 27% premarket on increased volume in response to Health Canada's sign-off on a clinical trial evaluating topical cream EB02 for the treatment of internal hemorrhoids. More news on: Edesa Biotech, Inc., Hea...
TORONTO, ON / ACCESSWIRE / September 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from Health Canada to begin a clinical study of its investigational drug, EB02, which the company is developing as a potential treatment for pat...
The following healthcare companies have filed prospectuses for mixed shelf offerings. More news on: electroCore, Inc., Edesa Biotech, Inc., Iovance Biotherapeutics, Inc., Healthcare stocks news, Read more ...
TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8...
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...